Patent ID: 6040306
Filing Date: 2000-03-21
Classification: A61K,A61P

Abstract:
A method of treating a person who has psoriasis which comprises administering to the patient an anti-psoriasis effective amount of an oxazolidinone selected from the group consisting of (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]-phenyl]-2-oxo-5-ox azolidinyl]methyl]acetamide,(S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]ac etamide,[4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl) phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,N-((5S)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxoo xazolidin-5-ylmethyl)acetamide,(S)-N-[[3-[5-(3-pyridyl)thiophen-2-yl]-2-oxo-5-oxazohdinyl]methyl]acetamide and(S)-N-[[3-[5-(4-pyridyl)pyrid-2-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide and pharmaceutically acceptable salts thereof.